The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma
Open accessAbstract
Background & Aims There is controversy over benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multi-center cohort study to compare overall survival between patients with HCV infection treated with DAAs vs patients who did not receive DAA treatment for their HCV infection after complete response to prior HCC therapy. Methods We conducted a retrospective cohort study of patients with HCV-related HCC who achieved a complete response to resection, local ablation, trans-arterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 healthcare systems throughout the United States and Canada. We used Cox proportional hazards regression to determine the association between receipt of DAA therapy, modeled as a time-varying covariate, and all-cause mortality, accounting for informative censoring and confounding using inverse probability weighting. Results Of 797 patients with HCV-related HCC, 383 patients (48.1%) received DAA therapy and 414 patients (51.9%) did not receive treatment for their HCV infection after complete response to prior HCC therapy. Among DAA-treated patients, 43 deaths occurred during 941 person-years of follow up, compared with 103 deaths during 526.6 person-years of follow up among patients who did not receive DAA therapy (crude rate ratio, 0.23; 95% CI, 0.16–0.33). In inverse probability-weighted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio [HR], 0.54; 95% CI, 0.33–0.90). This association differed by sustained virologic response (SVR) to DAA therapy; risk of death was reduced in patients with SVR to DAA therapy (HR, 0.29; 95% CI, 0.18–0.47) but not in patients without an SVR (HR, 1.13; 95% CI, 0.55–2.33). Conclusions In an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was associated with a significant reduction in risk of death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Constructing Inverse Probability Weights for Marginal Structural Models
Cole, S. R., & Hernan, M. A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn164 · Cited by 2,796
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis
Tabrizian, P., Jibara, G., Shrager, B., Schwartz, M., & Roayaie, S. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000710 · Cited by 903
Singal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817 · cited 1×
“In the absence of proven adjuvant agents, close surveillance after complete response may increase early tumor detection and minimize HCC-related mortality.(28,29) As previously reported, over two-thirds of patients with recurrence in our study were detected at an early stage (BCLC stage 0/A), and over 50% of those wit…”
Self-citationCabibbo, G., Petta, S., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Negrini, G., Ciccarese, F., Rapaccini, G. L., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.033 · Cited by 110
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“In HCV-associated HCC, two large multicenter studies from North America [198] and Italy [199] confirmed that eradication of HCV with direct-acting antiviral therapy does not increase risk of HCC recurrence and improves survival.”
Self-citationEASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Self-citation
Metadata
- Authors
- Singal, A. G., Rich, N. E., Mehta, N., Branch, A. D., Pillai, A., Hoteit, M., Volk, M., Odewole, M., Scaglione, S., Guy, J., Said, A., Feld, J. J., John, B. V., Frenette, C., Mantry, P., Rangnekar, A. S., Oloruntoba, O., Leise, M., Jou, J. H., Bhamidimarri, K. R., Kulik, L., Ioannou, G. N., Huang, A., Tran, T., Samant, H., Dhanasekaran, R., Duarte-Rojo, A., Salgia, R., Eswaran, S., Jalal, P., Flores, A., Satapathy, S. K., Kagan, S., Gopal, P., Wong, R., Parikh, N. D., & Murphy, C. C.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 157
- Issue
- 5
- Pages
- 1253-1263.e2
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2965705259
- Cited by
- 192
- References
- 5
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1053/j.gastro.2019.07.040
- The paper
- Singal, A. G., Rich, N. E., Mehta, N., Branch, A. D., Pillai, A., Hoteit, M., Volk, M., Odewole, M., Scaglione, S., Guy, J., Said, A., Feld, J. J., John, B. V., Frenette, C., Mantry, P., Rangnekar, A. S., Oloruntoba, O., Leise, M., Jou, J. H., . . . Murphy, C. C. (2019). Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.07.040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.